ISSUE 1338
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved tramadol hydrochloride extended-release (Ryzolt – Purdue) for treatment of moderate to moderately severe chronic pain in adults. Tramadol is already available in another extended-release formulation (Ultram ER) and in immediate-release tablets alone (Ultram, and others) and combined with acetaminophen (Ultracet, and others).
ANALGESIC ACTIVITY — Tramadol is a weak opioid agonist that also inhibits serotonin and norepinephrine reuptake; it is not scheduled as a controlled substance by the FDA. Tramadol 100 mg is about as effective for pain as aspirin 650 mg plus codeine 60 mg.1
PHARMACOKINETICS — Tramadol is converted by CYP2D6 to an active metabolite, O-desmethyltramadol, which has a much higher affinity than the parent drug for mu-opioid receptors. Studies in healthy volunteers found that serum concentrations
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1338c
Electronic, downloadable article - $45